Company Active LTD

Company profile

Magellan Life Sciences Limited

Coming Soon

Magellan Life Sciences Limited is a UK company with status active founded in 2018 based in London.

CRN
11417841
Founded
2018
Age
8

Overview

Legal name
MAGELLAN LIFE SCIENCES LIMITED
Region
London
Registered address
CANNON PLACE
78 CANNON STREET
LONDON
UNITED KINGDOM
ENGLAND
EC4N 6AF
Insolvency history
No

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
2

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

03 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

19 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

17 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNjIyNTQ0N2FkaXF6a2N4

Published 17 Sep 2024 15:21

15 Jun
2018

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2022
Funded years
2022, 2023, 2025
Age at first award
3 years

Projects

2025 Collaborative R&D Lead participant

BRAZZEIN - Development and Commercialization of Novel Low Calorie Food & Beverage Products

1 Apr 2025 to 30 Sep 2026

Awarded
£227,459
Total cost £324,941

Tackling sugar-related obesity and health challenges through developing a new generation of low calorie food & beverage products containing Brazzein as a sweetener.

2023 Collaborative R&D Lead participant

A novel approach to scaling up production of Brazzein - a natural, non-caloric protein sweetener and sugar alternative that can address UK and global sugar-related obesity epidemics and health challenges

1 Sep 2023 to 28 Feb 2025

Awarded
£182,580
Total cost £260,828

Tackling sugar-related obesity and health challenges through a novel approach to scaling up production of Brazzein - a natural, non-caloric sweetener and sugar alternative.

2022 Collaborative R&D Lead participant

BRAZZX - Developing a scalable and predictable fermentation process for Brazzein, a new, non-caloric protein sweetener

1 Mar 2022 to 31 Aug 2023

Awarded
£257,764
Total cost £368,234

Calorie gluttony due to sugar over-consumption has led to a worldwide epidemic of obesity and diabetes. The recent statistics highlighting the high propensity of obese and diabetic individuals to require hospitalization and intensive care during COVID infection is a wakeup call for the world to tackle the sugar reduction agenda with renewed urgency. Curre...

Product types

Collaborative R&D